Clarithromycin Extended-Release (ER) tablets treat various bacterial infections. Doctors commonly prescribe it for respiratory tract infections like acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia.
Respiratory Infections
Specifically, Clarithromycin ER targets infections caused by susceptible strains of bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. It’s also effective against atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae, which often require different antibiotics.
Skin and Soft Tissue Infections
Clarithromycin ER also finds use in treating skin and soft tissue infections caused by susceptible bacteria, although other antibiotics are often preferred as first-line treatment. This includes infections like cellulitis and erysipelas caused by Streptococcus pyogenes and Staphylococcus aureus (in cases of penicillin allergy).
Other Uses
Beyond these common uses, Clarithromycin ER is sometimes prescribed for other conditions, depending on the specific bacteria involved and the physician’s assessment. Consult your doctor to determine if it’s appropriate for your situation.
Dosage Considerations
| Acute bacterial exacerbations of chronic bronchitis | 500 mg once daily |
| Community-acquired pneumonia | 500 mg twice daily |
| Skin and soft tissue infections | 500 mg twice daily |
Note: This table provides general dosage information. Your doctor will determine the appropriate dosage based on your specific needs and the severity of your infection. Always follow your doctor’s instructions carefully.
Important Considerations
Remember to inform your doctor about all medications you are currently taking, including over-the-counter drugs and herbal supplements, as interactions can occur. Report any side effects, such as diarrhea or allergic reactions, to your doctor immediately. Clarithromycin ER is not suitable for everyone; discuss potential risks and benefits with your healthcare provider before starting treatment.
